ArticleIBRO neuroscience reports2026
Hesperidin mitigates cognitive and anxiety-like deficits by enhancing hippocampal antioxidant defenses, reducing neuroinflammation, and preventing neuronal apoptosis in a third-trimester-equivalent rat model of developmental ethanol neurotoxicity.
Article in IBRO neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ethanol exposure during brain development has been associated with hippocampal oxidative stress, neuroinflammation, and apoptosis, resulting in lasting cognitive and emotional deficits characteristic of fetal alcohol spectrum disorders (FASD). This study evaluated the neuroprotective potential of Hesperidin, a citrus flavanone with antioxidant and anti-inflammatory actions, against developmental ethanol neurotoxicity. Neonatal Wistar rats received ethanol (5.25 g/kg/day; 11.9% v/v) from postnatal days 2-10 and were subsequently treated intraperitoneally with Hesperidin (25, 50, or 100 mg/kg). Behavioral testing on days 39-45 using the Elevated Plus Maze (EPM) and Morris Water Maze (MWM) showed that ethanol markedly decreased open arm time (Oat%) and entries (OAE%) (P < 0.001, P < 0.01 vs Control), increased escape latency (P < 0.001), and reduced probe target time (P < 0.001 vs Control). Hesperidin at 50 and 100 mg/kg improved all indices (P < 0.05-0.01 vs Ethanol). Ethanol elevated hippocampal MDA and TNF-α (P < 0.001) while decreasing SOD (P < 0.01) and GSH-Px (P < 0.001), Hesperidin normalized these values (P < 0.01-0.001 vs Ethanol). GFAP and cleaved caspase-3 immunoreactivity were also reduced by hesperidin (P < 0.001 vs Ethanol). Overall, Hesperidin afforded dose-dependent neuroprotection by mitigating oxidative stress, inflammation, and apoptosis, thereby improving ethanol-induced behavioral impairments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.